Recent press releases
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
WHO WE ARE
The US HAEA is a non-profit patient advocacy organization dedicated to serving persons with angioedema.
We provide patients and families with a support network and wide range of services.
Executive Vice President
Contact Janet Long